TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19082229

Group type: COMPARATOR
Intervention: Oral prednisolone 0.5 mg/kg in 2 divided doses plus topical clobetasol ointment for 2 weeks
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Pentoxyfylline tablet 1200 mg/day in 3 divided doses for 2 weeks
Number of subjects: 40
Study: 16542472

Group type: EXPERIMENTAL
Intervention: Recombinant activated protein C (rhAPC)
Number of subjects: 0
Study: 12793211

Group type: EXPERIMENTAL
Intervention: Bleach plus light (using LumaArch, Optilux 500, and Zoom!)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Bleach alone (control group)
Number of subjects: 15
Study: 10915324

Group type: EXPERIMENTAL
Intervention: Education only intervention
Number of subjects: 383

Group type: EXPERIMENTAL
Intervention: Education/environment intervention
Number of subjects: 383

Group type: COMPARATOR
Intervention: Control
Number of subjects: 383

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 383
Study: 8857071

Group type: EXPERIMENTAL
Intervention: Lisinopril (L)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Atenolol (A)
Number of subjects: 16
Study: 1387609

Group type: EXPERIMENTAL
Intervention: ANF 4 ng.kg-1.min-1
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: ANF 8 ng.kg-1.min-1
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: ANF 16 ng.kg-1.min-1
Number of subjects: 14

Group type: COMPARATOR
Intervention: Vehicle (V)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: ANF (4, 8, 16 ng.kg-1.min-1)
Number of subjects: 14
Study: 6537871

Group type: EXPERIMENTAL
Intervention: Breakfast rich in vitamin A (337 micrograms of retinol equivalents, 48% as retinol and 52% as carotenoids)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Fasting blood samples
Number of subjects: 60
Study: 31664347

Group type: EXPERIMENTAL
Intervention: Adapted hip-hop dance practice (SG)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 18
Study: 28940451

Group type: EXPERIMENTAL
Intervention: Vilaprisan 0.5 mg/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vilaprisan 1 mg/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vilaprisan 2 mg/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vilaprisan 4 mg/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vilaprisan ≥1 mg/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vilaprisan
Number of subjects: 0
Study: 27764880

Group type: EXPERIMENTAL
Intervention: CT-based strategy including thoracic, abdominal, and pelvic CT in combination with fecal occult blood test
Number of subjects: 195

Group type: COMPARATOR
Intervention: Personalized strategy based on physicians' clinical judgment and patients' preferences
Number of subjects: 195
Study: 24848782

Group type: EXPERIMENTAL
Intervention: Sciatic nerve block (SNB) in addition to femoral nerve block (FNB)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Local infiltration of analgesia (LIA) in addition to femoral nerve block (FNB)
Number of subjects: 46
Study: 21688876

Group type: EXPERIMENTAL
Intervention: Daily estimated blood alcohol concentration (eBAC)
Number of subjects: 1350

Group type: EXPERIMENTAL
Intervention: Subjective intoxication
Number of subjects: 1350

Group type: EXPERIMENTAL
Intervention: Driving after drinking
Number of subjects: 1350

Group type: EXPERIMENTAL
Intervention: eBAC above legal limit
Number of subjects: 1350
Study: 19721382

Group type: EXPERIMENTAL
Intervention: Personal advocacy of influenza vaccination by community pharmacists in the intervention group.
Number of subjects: 1776

Group type: COMPARATOR
Intervention: Control pharmacy group (no advocacy).
Number of subjects: 1776
Study: 17962423

Group type: EXPERIMENTAL
Intervention: Immediate-release methylphenidate (50 mg)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Immediate-release methylphenidate (90 mg)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Osmotic-controlled extended-release methylphenidate (108 mg)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Osmotic-controlled extended-release methylphenidate (54 mg)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study: 15152054

Group type: EXPERIMENTAL
Intervention: Children measured under light Sevoflurane anesthesia
Number of subjects: 10

Group type: COMPARATOR
Intervention: Children measured awake
Number of subjects: 10
Study: 12228819

Group type: EXPERIMENTAL
Intervention: Atovaquone/proguanil (1 Malarone tablet per day for 20 weeks; n=148)
Number of subjects: 297

Group type: COMPARATOR
Intervention: Placebo (n=149)
Number of subjects: 297

Group type: EXPERIMENTAL
Intervention: Atovaquone/proguanil
Number of subjects: 297
Study: 9689557

Group type: EXPERIMENTAL
Intervention: 5 mg isosorbide dinitrate
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (clinically healthy subjects)
Number of subjects: 20
Study: 8082525

Group type: EXPERIMENTAL
Intervention: Acarbose (100 mg three times a day)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Glibenclamide (mean dose 4.3 mg/day)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Placebo (1 tablet three times a day)
Number of subjects: 96
Study: 2687557

Group type: EXPERIMENTAL
Intervention: Prazosin therapy
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Capoten monotherapy
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Combined therapy with glycosides and saluretics
Number of subjects: 88
Study: 30920983

Group type: EXPERIMENTAL
Intervention: Profound neuromuscular blockade (posttetanic count 1 to 3)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Moderate neuromuscular blockade (train-of-four count 1 to 3)
Number of subjects: 96
Study: 28578330

Group type: EXPERIMENTAL
Intervention: High-frequency rTMS over the dACC to mPFC for 5 sessions over 5 days
Number of subjects: 13

Group type: COMPARATOR
Intervention: Sham stimulation for 5 sessions over 5 days
Number of subjects: 13
Study: 26237112

Group type: EXPERIMENTAL
Intervention: Severe pain
Number of subjects: 394

Group type: EXPERIMENTAL
Intervention: Moderate pain
Number of subjects: 394

Group type: EXPERIMENTAL
Intervention: No pain
Number of subjects: 394

Group type: EXPERIMENTAL
Intervention: Arthritis pain
Number of subjects: 394
Study: 24221841

Group type: EXPERIMENTAL
Intervention: WE CALL (study initiated phone support/information provision)
Number of subjects: 186

Group type: COMPARATOR
Intervention: YOU CALL (participant can contact a resource person)
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: WE CALL
Number of subjects: 186
Study: 21226859

Group type: EXPERIMENTAL
Intervention: Slow moderate-pressure recruitment manoeuvre (SLRM)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Vital capacity recruitment manoeuvre (VICM)
Number of subjects: 16
Study: 19622979

Group type: EXPERIMENTAL
Intervention: Blunt needles
Number of subjects: 194

Group type: COMPARATOR
Intervention: Sharp needles
Number of subjects: 194
Study: 16706572

Group type: EXPERIMENTAL
Intervention: Pentoxifylline (400mg three times daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 14740578

Group type: EXPERIMENTAL
Intervention: Symptom management intervention using the Health Buddy device
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 11762562

Group type: EXPERIMENTAL
Intervention: 530-calorie breakfast after a 12-hour fast
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: 550-calorie meals (high-fat, high-protein, high-carbohydrate) after a 12-hour fast
Number of subjects: 28
Study: 9420396

Group type: EXPERIMENTAL
Intervention: Early appendicectomy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conservative management
Number of subjects: 0
Study: 8500242

Group type: EXPERIMENTAL
Intervention: Hydralazine-isosorbide dinitrate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: EPSS > or = 21 with Rs/THs > or = 2.5
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: EPSS < 21
Number of subjects: 0
Study: 3430953

Group type: EXPERIMENTAL
Intervention: Furosemide (mean dose = 172 mg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Bumetanide (mean dose = 4.3 mg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Furosemide
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Bumetanide
Number of subjects: 10
Study: 30442187

Group type: EXPERIMENTAL
Intervention: Letter
Number of subjects: 275

Group type: COMPARATOR
Intervention: No Letter
Number of subjects: 275
Study: 26891756

Group type: EXPERIMENTAL
Intervention: Ticagrelor 90 mg twice daily added to aspirin 81 mg/day
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo added to aspirin 81 mg/day
Number of subjects: 70
Study: 24837543

Group type: EXPERIMENTAL
Intervention: Validated telephone-based diet counseling intervention
Number of subjects: 464

Group type: COMPARATOR
Intervention: Published diet guideline (Control)
Number of subjects: 464

Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 464
Study: 22434340

Group type: EXPERIMENTAL
Intervention: Ceftriaxone 1 g diluted in 10 ml of lidocaine 1% administered periprostatically and ciprofloxacin orally
Number of subjects: 150

Group type: COMPARATOR
Intervention: 10 ml lidocaine 1% administered before TRUS gpb
Number of subjects: 150
Study: 20615145

Group type: EXPERIMENTAL
Intervention: Stent placement
Number of subjects: 60

Group type: COMPARATOR
Intervention: No stent placement
Number of subjects: 60
Study: 18665388

Group type: EXPERIMENTAL
Intervention: Antioxidant supplementation (including coenzyme Q(10))
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 16254100

Group type: EXPERIMENTAL
Intervention: Tamoxifen (2 years)
Number of subjects: 564

Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 564
Study: 12540320

Group type: EXPERIMENTAL
Intervention: Immediate catheterization and surgical intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 0
Study: 10190614

Group type: EXPERIMENTAL
Intervention: Closed reduction and plaster application
Number of subjects: 98

Group type: COMPARATOR
Intervention: Kapandji-pinning
Number of subjects: 98
Study: 7799039

Group type: EXPERIMENTAL
Intervention: Prolonged low-dose chemotherapy (CMF: cyclophosphamide 50 mg/m2 orally on days 1 to 14, methotrexate 15 mg/m2 intravenously on days 1 and 8, fluorouracil 350 mg/m2 intravenously on days 1 and 8) for 2 years
Number of subjects: 452

Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 452

Group type: EXPERIMENTAL
Intervention: Prolonged low-dose chemotherapy
Number of subjects: 452
Study: 2405920

Group type: EXPERIMENTAL
Intervention: Serum beta 2 microglobulin levels < 6 micrograms/mL
Number of subjects: 612

Group type: COMPARATOR
Intervention: Serum beta 2 microglobulin levels ≥ 6 micrograms/mL
Number of subjects: 612
Study: 6986896

Group type: EXPERIMENTAL
Intervention: Intranasal flunisolide (300 microgram/day)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Flunisolide
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate
Number of subjects: 60
Study: 31343945

Group type: EXPERIMENTAL
Intervention: High-intensity resistance exercise (5 sets of 10 repetitions at 75% of 1 repetition maximum)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Sham control (seated rest)
Number of subjects: 52
Study: 28732397

Group type: EXPERIMENTAL
Intervention: CSO events
Number of subjects: 0
Study: 25441259

Group type: EXPERIMENTAL
Intervention: GOALS assessment
Number of subjects: 10
Study: 24468920

Group type: EXPERIMENTAL
Intervention: Internet-based cognitive behavioural therapy with sudden gains
Number of subjects: 81

Group type: COMPARATOR
Intervention: Internet-based cognitive behavioural therapy without sudden gains
Number of subjects: 81

Group type: COMPARATOR
Intervention: Internet-based cognitive behavioural therapy with gradual gains
Number of subjects: 81
Study: 22694829

Group type: EXPERIMENTAL
Intervention: Ipilimumab (3 mg/kg q3w x 4 doses) + gp100 (1 mg q3w x 4 doses)
Number of subjects: 676

Group type: EXPERIMENTAL
Intervention: Ipilimumab (3 mg/kg q3w x 4 doses) + placebo
Number of subjects: 676

Group type: COMPARATOR
Intervention: gp100 vaccine + placebo
Number of subjects: 676
Study: 19946231

Group type: EXPERIMENTAL
Intervention: Transcatheter closure using Amplatzer Septal Occluder (ASO)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Open-heart surgery
Number of subjects: 100
Study: 17300626

Group type: EXPERIMENTAL
Intervention: Once-daily regimen of artemether-lumefantrine (AL) with 200 ml flavoured milk for 3 days
Number of subjects: 43

Group type: COMPARATOR
Intervention: Conventional twice-daily regimen of artemether-lumefantrine (AL) with 200 ml flavoured milk for 3 days
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Six-dose arm (twice-daily regimen)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Three-dose arm (once-daily regimen)
Number of subjects: 43
Study: 15673856

Group type: EXPERIMENTAL
Intervention: Pressure Support Ventilation (PSV)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Continuous Positive Airway Pressure (CPAP)
Number of subjects: 60
Study: 12845653

Group type: EXPERIMENTAL
Intervention: Antihistamine users
Number of subjects: 3133
Study: 9869600

Group type: EXPERIMENTAL
Intervention: Fedotozine (100 mg intravenous infusion)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 14
Study: 8888088

Group type: EXPERIMENTAL
Intervention: Aztreonam plus vancomycin
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Imipenem-cilastatin
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Aztreonam plus vancomycin and Imipenem-cilastatin
Number of subjects: 20
Study: 2072147

Group type: EXPERIMENTAL
Intervention: Individualized dosing of etoposide (target WBC nadir of 1,700/microL)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Fixed dose of etoposide (125 mg/m2/d)
Number of subjects: 45
Study: 7162387

Group type: EXPERIMENTAL
Intervention: Pangamic acid (6 tablets of 50 mg per day)
Number of subjects: 16
Study: 31694108

Group type: EXPERIMENTAL
Intervention: Optimized preoperative dietary management
Number of subjects: 40

Group type: COMPARATOR
Intervention: Traditional fasting program
Number of subjects: 40
Study: 28931149

Group type: EXPERIMENTAL
Intervention: B-GOS (2.7g daily for 7-15 days)
Number of subjects: 523

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 523
Study: 26195619

Group type: COMPARATOR
Intervention: Classic thermoplastic wrist splint
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Wrist splint with metacarpophalangeal unit
Number of subjects: 24
Study: 25103779

Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI) - 2 sessions
Number of subjects: 390

Group type: EXPERIMENTAL
Intervention: Personality-targeted interventions (PI) - 2 sessions
Number of subjects: 390

Group type: COMPARATOR
Intervention: Assessment Feedback/Information (AF/I) - 1 session
Number of subjects: 390
Study: 22468907

Group type: EXPERIMENTAL
Intervention: Therapist adherence to concrete cognitive therapy techniques
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Quality of the therapeutic alliance
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Baseline symptom severity × CT techniques interaction
Number of subjects: 105
Study: 19127072

Group type: EXPERIMENTAL
Intervention: Montelukast
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 17854740

Group type: EXPERIMENTAL
Intervention: Leflunomide 20 mg/day orally for 24 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Leflunomide 20 mg/day orally
Number of subjects: 0
Study: 16382063

Group type: EXPERIMENTAL
Intervention: Continued transfusion
Number of subjects: 79

Group type: COMPARATOR
Intervention: Transfusion-halted group
Number of subjects: 79
Study: 12564664

Group type: EXPERIMENTAL
Intervention: Otic powder (Auricularum)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Otic drops (Dex‐Otic)
Number of subjects: 67
Study: 9674632

Group type: EXPERIMENTAL
Intervention: Imidapril (angiotensin-converting enzyme inhibitor)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Amlodipine (calcium antagonist)
Number of subjects: 27
Study: 7534331

Group type: EXPERIMENTAL
Intervention: Octreotide (100 micrograms subcutaneously, twice daily for 4 weeks)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo (octreotide vehicle for 4 weeks)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Octreotide
Number of subjects: 11
Study: 2361714

Group type: COMPARATOR
Intervention: WHO standard ORS
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Super ORS
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Rice water electrolytes solution
Number of subjects: 75
Study: 375343

Group type: EXPERIMENTAL
Intervention: BAY g 5421 (Acarbose) 50 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: BAY g 5421 (Acarbose) 100 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: BAY g 5421 (Acarbose) 200 mg
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 31468418

Group type: EXPERIMENTAL
Intervention: Taurine supplementation (6 g/day) for 2 weeks prior to and 3 days following resistance exercise
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo supplementation
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Taurine supplementation (6 g/day)
Number of subjects: 29
Study: 28165562

Group type: EXPERIMENTAL
Intervention: icotinib hydrochloride
Number of subjects: 120

Group type: COMPARATOR
Intervention: erlotinib
Number of subjects: 120
Study: 25963602

Group type: EXPERIMENTAL
Intervention: Reduced food away from home
Number of subjects: 170
Study: 24238469

Group type: EXPERIMENTAL
Intervention: Weight rehabilitation (target weight between the 15th and 20th BMI percentile)
Number of subjects: 172
Study: 21890887

Group type: EXPERIMENTAL
Intervention: Hyperbaric bupivacaine 10 mg
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Isobaric bupivacaine 10 mg
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Hypobaric bupivacaine 10 mg
Number of subjects: 89
Study: 18984669

Group type: EXPERIMENTAL
Intervention: Hyperinsulinemic euglycemic clamp with LPS (insulin infusion at 10 or 40 mU.m(‐2).min(‐1))
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group (hyperinsulinemic euglycemic clamp without LPS)
Number of subjects: 18
Study: 17087800

Group type: EXPERIMENTAL
Intervention: Tadalafil 10 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tadalafil 20 mg
Number of subjects: 0
Study: 15019315

Group type: EXPERIMENTAL
Intervention: Frequency-Doubling Technology (FDT) perimeter
Number of subjects: 40
Study: 11520781

Group type: EXPERIMENTAL
Intervention: PEG‐rHuMGDF 1 microg/kg
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: PEG‐rHuMGDF 3 microg/kg
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 9716581

Group type: EXPERIMENTAL
Intervention: Interferon-alpha (IFN-alpha)
Number of subjects: 322

Group type: COMPARATOR
Intervention: Conventional chemotherapy
Number of subjects: 322
Study: 7934716

Group type: EXPERIMENTAL
Intervention: Willingness to pay (WTP) for a hypothetical intervention offering a 99% chance of healthy lung functioning and a 1% chance of death
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Standard gamble
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Test-retest reliability of WTP
Number of subjects: 102

Group type: COMPARATOR
Intervention: Health status and preference measurements (excluding WTP)
Number of subjects: 102
Study: 2954145

Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (CY 222) at 90 anti‐Xa units/kg bolus + 1,000 anti‐Xa units/hour infusion (regimen 1)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Standard heparinization regimen (100 IU/kg) (regimen 2)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (CY 222) at 300 anti‐Xa units/kg bolus (regimen 3)
Number of subjects: 8
Study: 31399910

Group type: EXPERIMENTAL
Intervention: Whole grain diet (WG-D)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Fruit and vegetable diet (F&V)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Combined whole grain and F&V diet (WGFV-D)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 75
Study: 30343856

Group type: EXPERIMENTAL
Intervention: Nurse-led care
Number of subjects: 517

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 517
Study: 28393773

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (Dex) 0.5 μg/kg/h
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 26381921

Group type: EXPERIMENTAL
Intervention: Endurance Training (ET)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Circuit Training (CT)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Relaxing Training (RT)
Number of subjects: 40
Study: 24267363

Group type: EXPERIMENTAL
Intervention: Oral desensitization (200 mL of cow's milk daily)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Elimination diet
Number of subjects: 31
Study: 22122955

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) administered perorally after shooting
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group (no NAC)
Number of subjects: 34
Study: 18366658

Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 16981641

Group type: EXPERIMENTAL
Intervention: Contextual information provided in social norms marketing approach
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 12716664

Group type: EXPERIMENTAL
Intervention: Stearidonic acid (SDA)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Alpha-linolenic acid (ALA)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Eicosapentaenoic acid (EPA)
Number of subjects: 30
Study: 12743836

Group type: EXPERIMENTAL
Intervention: Cast gold partial crowns (CGPC)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Ceramic partial crowns (CPC)
Number of subjects: 64
Study: 9790159

Group type: COMPARATOR
Intervention: Nimodipine monotherapy
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Nimodipine with carbamazepine augmentation
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Nimodipine-carbamazepine combination
Number of subjects: 30

Group type: COMPARATOR
Intervention: Verapamil substitution for nimodipine
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Nimodipine transition to isradipine
Number of subjects: 30